黏膜IL13RA2表达预测克罗恩病对抗TNF治疗无应答
该研究在阿达木单抗和维得利珠单抗治疗患者中验证黏膜IL13RA2表达对抗TNF无应答的预测价值,并探索其上游调控机制。结果显示,治疗前黏膜IL13RA2表达升高特异性地预测抗TNF无应答(抗TNF组AUROC=0.90,P<0.001;维得利珠单抗组AUROC=0.63,P=0.30),且与黏膜TNF负荷增加相关。
要点
- 治疗前黏膜IL13RA2表达升高可特异性预测抗TNF治疗无应答。
- 抗TNF无应答者基线黏膜TNF负荷增加,TNF mRNA与IL13RA2表达显著相关。
- 基线血清TNF水平在无应答者中显著降低,并与IFX诱导期血清水平呈负相关。
核心结论
- 黏膜IL13RA2表达升高与克罗恩病患者黏膜TNF负荷增加相关,并特异性地预测抗TNF治疗耐药,可能是治疗选择或调整抗TNF药物剂量的潜在生物标志物。
研究设计与样本
- 研究在阿达木单抗和维得利珠单抗治疗的患者队列中检测黏膜IL13RA2表达,并对公开的IFX治疗患者微阵列数据应用加权基因共表达网络分析以识别上游调控因子,同时检测首次IFX暴露前的部分血清蛋白(包括TNF)。
主要发现
- 开始生物治疗前黏膜IL13RA2表达升高特异性地预测抗TNF无应答:抗TNF组AUROC=0.90,P<0.001;维得利珠单抗组AUROC=0.63,P=0.30。
- 基线活检中,未来抗TNF无应答者的TNF驱动通路显著富集(P=5.0×10^-34)。
- 无应答者基线黏膜TNF负荷增加(P=0.02),且TNF mRNA与IL13RA2表达显著相关(ρ=0.55,P=0.02)。
- 无应答者基线血清TNF水平显著降低(P=0.04),并与第6周IFX血清诱导水平呈负相关(r=-0.45,P=0.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ileocolonic expression of IL13RA2 has been identified as a predictive marker for nonresponsiveness to infliximab (IFX) in patients with Crohn's disease (CD). AIM: To validate the IL13RA2 biomarker, study its anti-TNF specificity and get a better understanding of the underlying biology driving its expression. METHODS: IL13RA2 mucosal expression was studied in a cohort of adalimumab and vedolizumab treated patients. To identify the upstream regulators of anti-TNF nonresponsiveness, weighted gene co-expression network analysis was applied on publicly available microarray data of IFX-treated patients. Selected serum proteins, including TNF, were measured prior to first IFX exposure and compared between healers and nonhealers. RESULTS: Increased mucosal IL13RA2 expression prior to start of biological therapy was predictive for anti-TNF nonresponsiveness specifically (AUROC, area under the curve = 0.90, P < 0.001 in anti-TNF vs AUROC = 0.63, P = 0.30 in vedolizumab treated patients). In baseline biopsies, TNF-driven pathways were significantly enriched in future anti-TNF nonhealers (P = 5.0 × 10-34 ). We found an increased baseline mucosal TNF burden in nonhealers (P = 0.02), and TNF mRNA correlated significantly with IL13RA2 expression (ρ = 0.55, P = 0.02). Baseline serum TNF levels were significantly lower in nonhealers (P = 0.04), and correlated inversely with IFX serum induction levels (r = -0.45, P = 0.002 at week 6). CONCLUSIONS: Increased mucosal IL13RA2 expression is associated with an increased mucosal TNF burden in CD patients. In view of its specificity for prediction of anti-TNF therapy resistance, mucosal IL13RA2 expression is a potential biomarker for therapy selection and/or for the need of increased anti-TNF drug dosing.
引用
- Verstockt B, Verstockt S, Creyns B, et al. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. Aliment Pharmacol Ther. 2019. PMID: 30663072. doi:10.1111/apt.15126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。